Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reckitt Bids Up Bayer For Schiff Nutrition

This article was originally published in The Tan Sheet

Executive Summary

Reckitt says its $42 per-share cash offer values Schiff at around $1.4 billion, 23/.5% more than Bayer’s $1.2 billion bid, roughly $34 per share, for the Salt Lake City-based firm.

You may also be interested in...

Kind’s Specific Ingredient Claims Remain Airborne After General Comparison To Clif Bar Line Grounded

National Advertising Division says a TV commercial Kind previously aired claiming “75% less sugar than the leading Clif bar” made an unfair “line claim.” But Kind says "ultimately this issue is moot" as it stopped using the "commercial (which takes place on an airplane) many months ago in light of the COVID-19 pandemic.”

No Hiding Bogus Coronavirus Claims From US Regulators In Social Media Or With Vague Terms

“I don’t know if there’s a misconception that a different set of adverting rules apply to social media," says FTC attorney Christine DeLorme during FDLI conference. The FTC also sees "a lot of attempts at disclaimers. They might say, ‘Of course there’s no cure for COVID, but...’"

Waiting For Cannabidiol Guidance? US FDA Reminds Industry Of ‘Many Other Requirements’

Two months after submitting CBD enforcement draft guidance for OMB review, FDA published separate draft guidance on studies for bioequivalents of an approved cannabidiol-based drug. But the draft guidance that the supplement industry awaits in pitched anticipation remains under review.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts